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Abstract 
The prevalence of obesity in the United States of America has 
increased over the last twenty years. This prevalence has led to an increase 
in the study of the hormones involved control of metabolism and satiety to 
further understand the factors involved in obesity. One of these hormones is 
melanin-concentrating hormone (MCH). Many of the studies of MCH focus on 
the brain, while little work is done on the peripheral tissues. In adipose cells 
stimulation with MCH causes a release of leptin through activation of melanin­
concentrating hormone receptor-1, a G-protein coupled receptor. MCHR1 
becomes desensitized after activation with MCH, but the method of 
desensitization is unknown. ELISA studies show that internalization of the 
receptor is low unless proteins in the clathrin pathway are incorporated, so 
another method of desensitization must be occurring. Through sucrose­
gradient centrifugation MCHR1 co-localizes with caveolin-1, suggesting a role 
for lipid rafts in receptor dynamics. This thesis will examine the extent of 
interaction between caveolin-1 and MCHR1. The first aim will be to determine 
the degree of co-localization of receptor and caveolin-1 under varying 
conditions. The second aim will be to analyze the dynamics of the MCHR1 
within caveolae after MCH stimulation and with expression of the arrestins. 
The goal will be to better understand the interaction between caveolae and 
MCHR1 and possibly provide insight into MCHR1 's mode of desensitization. 
1 
Introduction 
Obesity: a Growing Epidemic in the United States 
Obesity is a growing epidemic throughout the United States. According 
to the Center for Disease Control and Prevention (CDC), one third of all adults 
and a staggering 17 percent of children are obese (Flegal et al., 2010). In 
i 985, oniy 8 states had a high obesity incidence of 10 to 15 percent. Twenty­
five years later, 12 states have an obesity incidence over 30 percent (Flegal, 
2012). This dramatic increase is detrimental to the overall health of the nation. 
Overweight and obese individuals have a greater propensity to develop 
serious diseases, which include coronary heart disease, type 2 diabetes, 
hypertension, respiratory problems, various cancers and reproductive 
disturbances (Must, 1999; Pasquali et al., 2003). 
This increase in obesity incidence has spurred numerous companies to 
attempt to develop an easy cure. Weight-loss pills containing stimulants and 
crash diet plans offer quick results with unhealthy side effects. One example 
of a risky diet pill is fenfluramine/phentermine (nicknamed fen/phen), which 
caused pulmonary hypertension and heart valve problems in users; some of 
these complications proved to be fatal (Berg, 1999). Healthy eating habits and 
exercise have shown results for those willing to do the work. But, what if an 
individual does put in the time and effort and a healthy lifestyle still does not 
work? In these cases, it is possible that hormonal imbalance is causing 
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decreased metabolism and weight gain. Is there a safer way of developing a 
drug to boost an individual 's weight loss? 
Hormone pathways are complex and depend on numerous inputs from 
the body and external feedback to maintain balance (Jehan et al. , 1993; 
Alkemade et al., 2005; Wintermantel et al., 2006). Hormones monitor 
numerous functions in the body, one of which is the drive to take in food. The 
regulation of food intake and metabolism is complex, with numerous 
hormones and signaling pathways contributing to the overall process (Wang 
et al., 2002 ; Berthoud, 2008). The proteins that control hormonal pathways 
are broken down into four distinct subgroups: tyrosine-derivatives, steroids, 
peptides and proteins. While there are different types, each hormone acts 
basically in the same way: by attaching to a receptor and causing a cellular 
change within the targeted ceiis. As hormones and their receptors are 
studied, they provide an important method of targeting diseases through 
treatment with hormones themselves or with receptor blockers to inhibit 
hormonal action. 
One well-known and effective hormonal drug is the oral contraceptive 
pill, used by 10.7 million women in the United States (Mosher et al. , 2010). 
Hormonal contraception works by overriding the natural cycle of hormones in 
a woman's body and prevents pregnancy from occurring. The main type of 
contraception is a combination of estrogen and progesterone that ensures no 
egg maturation and no ovulation (Hatcher, 1998; Rivera al., 1999). In 
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contrast, examples of treatments that block receptors include a- and r3-
blockers, which act upon the a- and r3- adrenergic receptors. These receptor 
agonists help to treat numerous diseases from cardiac arrhythmias and 
hypertension to post-traumatic stress and social anxiety disorders (Frishman 
et al. , 2005). 
Since both administration of hormones and receptor blockers have 
been used successfully, it is possible that there are parts of the satiety 
pathway that could be targeted as a treatment for obesity. There are 
numerous hormones involved in hunger and satiety, making targeting in this 
way a complex task. Understanding how each hormone that contributes to 
metabolism and food intake works is vital to successfully treating the growing 
numbers of obese individuals. This thesis will focus on one hormone in the 
pathway, melanin-concentrating hormone, its function and behavior within the 
cell membrane. 
G-Protein Coupled Receptors 
Many hormones utilize G protein-coupled receptors (GPCRs) for 
signaling. GPCRs have seven hydrophobic a-helix trans-membrane domains 
with an internal carboxyl-terminal end, and external amino-terminal end. They 
interact internally with guanine nucleotide binding proteins or G-proteins. 
are numerous types of GPCR families, where the external sections of 
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the receptor interact with specific hormones to cause a cellular response 
(Rosenbaum et al., 2009). 
Internally, G-proteins function in a similar way, with signal specificity 
produced by the types of G-protein subunits used (Figure 1 ). The G-protein is 
a heterotrimer that is comprised of two protein subtypes, the a, and �Y 
obligate dimer and each plays a part in the activation of the GPCR. The a-
subunit is a GTPase that acts upon guanosine diphosphate (GDP) when the 
G protein is inactive. The GTP is bound to the a-subunit when the GPCR is in 
a resting state (Figure 1 A). After the receptor is activated through ligand 
binding, the a-subunit becomes activated and releases GDP then binds to 
guanosine triphosphate (GTP) (Figure 1 B). The conformational change in the 
a-subunit after ligand binding also causes the �y-subunit to dissociate. After 
dissociation both the a-subunit and the fjy-subunit initiate various internai 
signaling cascades through interactions with effector molecules (Figure 1 C). 
After this interaction, the a-subunit catalyzes the hydrolysis of GTP to GDP, 
which restores the association between the a-subunit and the r3v-complex 
(Figure 1 D). This returns the GPCR to its resting state, where it can begin the 
process again if hormone is available (Boguski and McCormick, 1993). 
Depending upon the type of a-subunit, the GPCR can act in many 
different ways. The three well-known pathways are Gila, Gs and Gq and each 
activates a different internal signaling pathway depending on its a-subunit 
(Figure 2). The cyclic AMP (cAMP) pathway is either stimulated by Gs 
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signaling or inhibited by Gila· Through adenylyl cyclase, these two G-proteins 
can change the generation of cAMP and indirectly effect the activity of protein 
kinase A (PKA) (Figure 2A&B). The Gq pathway works not on cAMP but uses 
Phospholipase C (PLC) to cleave membrane bound PIP2 into inositol 
triphosphate ( IP3) and diacylglycerol (DAG) (Figure 2C). Once cleaved, DAG 
stays in the membrane and activates Protein Kinase C (PKC) with the 
assistance of calcium, while the IP3 acts upon the IP3 receptors in the 
endoplasmic reticulum to release Ca2+ stored there. Finally, the G0 type of 
receptor also activates the PKC pathway. For both the Gq and G0 pathways, 
the activation of PKC causes RAS to be phosphorylated and signal to RAF 
and activates the MAPK pathways (Figure 2C&D) (Marinissen and Gutkind, 
2001 ). These internal signaling cascades can cause numerous biological 
responses, the most common being a change in the transcription of targeted 
genes within the cell. 
Due to the different nature of GPCR's, hormones can have both short­
and long-term effects. In the short term, increases in cellular calcium can 
cause endocytosis of stored hormone, much like the release of thyroid­
stimulating hormone (TSH) from the pituitary in response to the Gq pathway of 
the thyrotropin-releasing hormone (TRH) receptor. This release of TSH 
causes the thyroid to release thyroid hormone into the bloodstream (Blake, 
1974). In the long term, cells can alter transcription due to hormone 
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stimulation. One example is the stimulation of the adrenal glands with 
adrenocorticotropic hormone (ACTH), which uses a Gs pathway to cause 
release of cortisol from the adrenal glands. The cortisol released causes an 
increase in blood sugar due to a change in the transcription of glucagon and a 
suppression of the immune system (Marieb and Hoehn, 2010). 
The cyclic activation of a GPCR means that it can be continuously on. 
This continuous stimulation would be counterproductive for the cell, so there 
are numerous methods of terminating receptor signaling. First, having 
hormones that degrade allows for physical removal of the stimulus. Second, 
the receptor can be modified to become unresponsive. These modifications 
can be through phosphorylation, or ubiquination or even interactions with 
other moiecuies that can inactivate the receptor. Third, removai of the 
receptor from the membrane can cause desensitization, as there is no 
receptor to signal present on the membrane (Ferguson et al., 1998). 
Clathrin-mediated Endocytosis 
most characterized pathway for receptor internalization is clathrin­
mediated endocytosis. Thomas Roth and Keith Porter took the first electron 
micrograph images of clathrin-coated pits in 1964 (Roth and Porter, 1964). In 
1975, Barbara Pearse discovered and characterized the clathrin molecule that 
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was the cause of the pits seen by Roth and Porter (Pearse, 1976). The basic 
pathway of the clathrin-coated pit is simple: a pit (or invagination) is formed on 
the surface of the membrane coated in target proteins, and then the pit is 
physically removed from the membrane (Figure 3A). There are quite a few 
molecules that facilitate this type of removal from the membrane. One is 
clathrin, which forms a defined coat on the internal side of the invagination. 
There are over fifty other proteins that can be involved in the three-step 
process of internalization. The first step involves proteins that select the 
membrane area targeted for internalization and facilitate the attachment of 
clathrin and the coat proteins to the membrane (Traub, 2003). In the second 
step, proteins are involved in attaching the internalizing vesicle to actin and 
maintaining the energy dynamics needed to move the vesicle within the cell 
(Quaimann et ai., 1999). The proteins invoived in the third step help remove 
the protein coat from the clathrin-vesicle so that it can fuse with an endocytic 
vesicle which will then break down the targeted molecules (Masso I et al., 
2006). 
To identify these endocytic vesicles, certain G-proteins, unrelated to 
the heterotrimeric G-proteins previously mentioned, that are localized to 
specific vesicles are targeted. For identification of clathrin-coated vesicles and 
early endocytic vesicles, RAS-related protein 5 or Rab5 is used (Stenmark et 
al., 1995). Late endosomes are identified by RAS-related protein 7 or Rab? 
(Cantalupo et al., 2001 ). The proteins associated with vesicle internalization 
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are quite efficient, and the process of internalization can occur within a minute 
of the first clathrin molecule joining with the membrane. This can occur at 
rates of 0.35-0.45/minute-measured as the ratio of external radioactivity to 
internal radioactivity with iodinated EGF (Huang et al., 2004). 
Two molecules that are part of the clathrin-mediated pathway are r3-
Arrestin 1 and (3-Arrestin 2. These are proteins that are involved in alternative 
cargo adaption specific to internalization of certain types of receptors, such as 
the r3r adrenergic receptor. They bind to phosphorylated forms of the GPCR's 
and uncouple them from signaling pathways (Shenoy and Lefkowitz, 2003). 
The two r3-Arrestins help initiate the clathrin-mediated endocytic pathway that 
efficiently internalizes the receptor. These proteins have been more broadly 
linked to the facilitation of internalization of many more types of GPCR's. 
interactions between the arrestins and ERKi /2 and parts of the JAK/STAT 
pathway help facilitate cooperation between the signaling cascades and the 
GPCR (Luttrell and Lefkowitz, 2002). Overall, clathrin-mediated endocytosis is 
a complex pathway that efficiently removes receptors from the membrane and 
facilitates desensitization (Oakley et al., 1999). This is not the only method of 
desensitization, however, and interaction of receptor with lipid rafts can affect 
the dynamics of the receptor's activation and desensitization (Gustavsson et 
al., 1999). 
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Lipid Rafts 
Lipid rafts were first noticed in electron micrographs in the 1950's by 
Palade, seeing what were described as invaginations in the plasma­
membrane that were 'flask-shaped' (Palade, 1953). The invaginations were 
distinguishable from the clathrin-coated pit because they lacked a coat 
molecule, and the name caveolae was adopted, which is Latin for 'little caves'. 
These areas on the membrane are classically lighter in density than the rest 
of the lipid membrane due to high levels of cholesterol and sphingolipids 
(Fridriksson et al., 1999). They are characterized as being detergent insoluble, 
and so will resist being broken down like the rest of the membrane when a 
non-ionic detergent is applied to cells (Brown and Rose, 1992). 
There are three structural proteins, caveolin 1, 2, and 3, that are 
invoived in maintaining the stabiiity of caveoiae on the membrane. The most 
prominently expressed of the three is caveolin 1, which is present in 
endothelial, f ibrous and adipose tissues. Caveolin-1 oligomerizes to help form 
an invaginated structure with both the C and N termini intracellular (Parton, 
1996; Smart et al., 1999). Caveolin 2 is co-expressed with caveolin 1, but the 
loss of caveolin 2 does not affect the formation of caveolae, whereas the loss 
of caveolin 1 would affect formation of caveolae (Fujimoto et al., 2000). Finally, 
caveolin 3 is expressed only in skeletal and smooth muscle cells. The loss of 
caveolin 3 causes cardiac myopathy, which indicates a regulatory or signaling 
role for caveolin 3. In cases where the caveolin proteins are knocked out in 
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mice, there is normal fetal development but a decrease in life span due to 
issues with angiogenic responses, hypertrophic lungs and the aforementioned 
cardiomyopathy (Tang et al., 1996; Figarella-Branger et al., 2003). 
Caveolae and Internalization 
Caveolin is synthesized as a membrane protein in the endoplasmic 
reticulum, is sent to the golgi and is eventually packaged into lipid rafts. It is 
important to note that the pool of caveolin in the golgi is detergent soluble; the 
insoluble nature of caveolae arises when the cholesterol, sphingolipids and 
caveolin complex together (Monier et al., 1995). On the membrane itself, the 
caveolin proteins within caveolae are immobile: fluorescence recovery after 
photobleaching intracellular caveolin has a high mobile fraction, but caveolin 
associated with the membrane has a very low mobile fraction, about 5 to 1 O 
percent (Thomsen et al., 2002). Caveolae have been shown to internalize in 
response to administration of okadaic acid (a phosphatase inhibitor) and in 
response to infection with the Simian virus 40 (Parton et al., 1994; Pelkmans 
et al. , 2001 ) . After internalization, the structures remain as a stable unit, and 
they can either fuse with a caveosome, independently from a Rab5, or they 
can shuttle the membrane segment to an early endosome dependent upon 
Rab5. A caveosome is a large internal endosome containing caveolin-1. In 
either case the oligomerized caveolin can be shuttled back to the membrane, 
to maintain the caveolae structure (Figure 3B)(Nichols, 2003). 
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Caveolae and Signaling 
Caveolae play an important function in cellular signaling. Numerous 
cellular receptors have been immunoprecipitated in conjunction with caveolin 
proteins. Certain pathways like eNOS and Src kinase are dependent on the 
presence of caveolins and caveolae domains for proper function (lgarashi et 
al., 1999). Interestingly, caveolin-1 is known to interact with Ga subunits (s,o 
and i), H-RAS and Src kinases, but only when they are inactive. If the 
receptors are mutated so that they cannot signal, they do not associate with 
caveolin-1. This indicates that caveolins preferentially associate with inactive 
receptors and are dissociated from activated receptors (Li et al., 1995, 1996; 
Song et al., 1996). 
Caveolae, or caveolin, also interact with insulin receptors in adipocytes. 
In adipose tissue, insulin receptors move into and out of caveolae. The 
receptors move into caveolae to signal, and a decrease in signaling is seen 
when choiesterol is inhibited (Gustavsson et al., 1999). This means that the 
interaction between caveolae and the insulin receptor facilitates proper 
signaling for the receptor. In the cases of vascular endothelial growth factor 
(VEGF) and epidermal growth factor , they do not move into and out of 
caveolae. For these receptors, instead of a reduction in signaling due to 
cholesterol depletion, there is an increase in activation if caveolae domains 
are removed (Furuchi and Anderson, 1998; Labrecque et al., 2003). 
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Finally, an important function of caveolin lies in its effect on lipid 
regulation, through interactions with lipid molecules. There is a large amount 
of caveolin present in adipose tissue, with an almost a ten-fold difference 
between undifferentiated adipose cells and fully differentiated adipose cells 
(Fan et al., 1983). Adipose cell membranes are thought to be comprised of up 
to 40 percent caveolae domains (Parton and Simons, 2007). Caveolin has 
been shown to interact with cholesterol, fatty acids and lipid droplets in cell 
culture and in vivo (Sleer et al., 2001 ). It has a role in the uptake of fatty acids 
into the cells, along with the transport of cholesterol within the cell (Pol et al., 
2001, 2004). It is possible that for different receptors, the interaction between 
each of the caveolae components-cholesterol, sphingolipids and caveolin­
can regulate the activation of the receptor to produce the most effective 
signaiing potentiai required for the cell type (Chini and Parenti, 2004). 
Hormonal Regulation of Obesity: Leptin 
Leptin is an adipose-derived hormone that plays a very important part 
in the satiety pathway. In 1994, Jeffery M. Friedman discovered that loss of 
functional leptin was the cause of an obese strain of mice that had developed 
in the Johnson Laboratory's mouse colony in the 1950's (Zhang et al., 1994). 
Leptin is now known to signal from the adipose tissue into the hypothalamus 
in the brain, crossing the blood-brain barrier (Banks et al., 1996). It acts upon 
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neuropeptide Y neurons to inhibit the release of neuropeptide Y (an appetite 
stimulator) and by doing so, decreases food intake (Morrison et al., 2005). 
After the discovery of leptin, the obese mice in the Johnson 
Laboratory's colony could be classified into two different subgroups. The first 
is an ob/ob genotype that has either a loss of leptin production or a knockout 
of the gene and a db/db genotype that has a !oss of function of a knockout of 
the leptin receptor (Orel et al., 2006). Leptin ob/ob knockout mice show a 
dramatic increase in weight compared to wild-type that is largely the result of 
increased adipose tissue, which is due to hypometabolic rates and 
hyperphagia. Leptin knockout mice also showed an insulin intolerance and a 
reduction in reproductive abilities, both of which have also been seen in 
obese individuals as mentioned previously (Berg, 1999; Pasquali et al., 2003). 
After the discovery of leptin and its functional role in appetite control, it 
seemed that leptin might be the cure for obesity, so work was done to try to 
counteract the effects that leptin loss had on the ob/ob mice. After 
administration of leptin, knockout mice showed a decrease in body weight and 
a corresponding loss of fat tissue. They also regained their insulin sensitivity 
(Cohen et al. , 2001 ). Initially, it was thought that leptin could be the much 
sought-after cure for obesity in humans, producing a 'magic pill' to treat 
obesity. Using leptin as an anti-obesity treatment, however, only worked in an 
extremely small number of cases, which aptly corresponded to those who had 
a deficiency of leptin as the cause of their obesity. Leptin was successfully 
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used to treat a congenital leptin deficient child; she displayed marked 
hyperphagia at the age of 4 months, and at age 9 weighed 94.4 kilograms 
(99.9 percentile). Two weeks after leptin administration, she started losing 
weight, for a total of 15.6 kg within the year (Farooqi et aL, 1999). While leptin 
treatment worked in this case, it does not for the majority of the population 
(Bell-Anderson K.S. and Bryson J.M., 2004). 
Leptin is produced in the adipose tissue and the amount of leptin 
secreted in the blood is proportional to the amount of fat that is in the body 
(Klein et al., 1996). This means that obese individuals are producing more 
leptin, which would be acting on the same number of receptors. Obese 
individuals have a limited number of receptors available. There are also 
higher quantities of leptin in obese individuals' bloodstreams compared to thin 
individuais. This limits the number of available receptors to respond when 
there is an increase in leptin in response to food intake, which causes the 
negative feedback pathway to be less efficient, and eating continues 
(Rahmouni et al., 2002). This issue can lead to an even greater increase in 
weight, making correction of the imbalance important for successful weight 
regulation. 
Leptin has turned out to not be the magic drug that it was originally 
though to be. The hormonal control of satiety is much more complex than 
originally assumed, and each part of the pathway acts in a different manner. 
Therefore, it is important to understand the entire feedback pathway used to 
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produce leptin in order to more fully treat the imbalance occurring in obese 
individuals. This has led to an investigation into another hormone in the 
satiety pathway: melanin-concentrating hormone (MCH). 
Melanin-concentrating Hormone 
Melanin-concentrating hormone was first discovered in Teleost fish 
where it concentrates melanin and causes a lightening of the scales 
(Kawauchi et al., 1983). When it was identified in mammals, however, it was 
discovered that it has little to do with melanin control and much to do with the 
satiety pathway (Trites et al., 2001 ) . Melanin-concentrating hormone is 
composed of 19-amino acids and forms a ring (Figure 4). A disulfide bond 
between two centrally placed cysteine residues (Cys7 and Cys16) defines this 
ring structure, which is essential for proper hormone function (Lebl et al., 
1988). MCH expression is highly concentrated in the perikarya of the lateral 
hypothalamus and the zona incerta. Release of MCH from the perikarya can 
be stimulated through administration of potassium and calcium (Naito al., 
1985). Additionally, expression of the receptor is distributed throughout the 
body-which points to a neurotransmitter or a neuromodulator type role for 
the hormone (Bittencourt et al. , 1992). It is possible that MCH has many 
functions throughout the body, in both behavioral and physical responses. 
Physiologically, rats with high expression of, or treated with MCH were mildly 
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obese and had significant insulin resistance. Pancreatic islets were 
hypertrophied, indicating that MCH might be an activator of insulin production 
(Ludwig et al., 2001 ). Additionally, the receptor for MCH is found in beta-cells 
in the pancreas, further supporting a larger role for MCH in metabolism 
(Pissios et al., 2003). Treating rats with a MCH receptor inhibitor mimicked 
treatment with an antidepressant drug and eased social anxiety (BorrnNsky et 
al., 2002; Chen, 2002). 
MCH is known to be an appetite activator, and when administered 
orally it causes an increase in food consumption within the hour and the 
effects last up to six hours (Qu et al., 1996). Mice given MCH for long periods 
of time show increased weight, and if there is a universal overexpression of 
MCH in mice obesity and insulin resistance is observed (Ludwig et al., 2001 ) . 
interestingiy, ieptin obiob mice show an increase in MCH expression in the 
hypothalamus, possibly as an attempt to signal a greater response for leptin 
(Figure 5). Additionally, when mice are in a fasting state they have an 
increase in expression of MCH. After fasting for 24 to 48 hours there is an 
increase in mRNA for MCH to three times normal expression rates (Bertile et 
al., 2003). It is possible that leptin secretion, in addition to stimulating NPY 
and melanocyte-stimulating hormone, also feeds back negatively upon MCH 
secretion, forming an efficient feedback pathway to regulate satiety control 
(Figure 5). 
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Melanin-Concentrating Hormone Plays a Role in Appetite 
When MCH is knocked out in mice, there is a lean phenotype observed 
due to hypophagia and a corresponding hypermetabolic rate (Trites et al., 
1998). When the receptor for MCH is knocked out in mice, a lean phenotype 
is also observed and the mice are also resistant to diet-induced obesity. 
These knockout mice display hyperphagic and hypermetobolic symptoms 
(Chen, 2002). Work done on an antagonist for MCH receptor has shown that 
when antagonist is administered over a long period of time there is a dramatic 
decrease in the weight of diet-induced obese mice (Takekawa et al., 2002). 
This supports a role for MCH in the regulation of metabolism despite food 
intake. If this could be successfully applied in humans, it could effectively help 
obese individuals lose weight without serious side effects like the cardiac 
complications seen after use of fen-phen (Berg, 1999). There are two 
receptors for MCH, the first is present in all mammals while the second is 
found in only dogs and primates (Tan et al., 2002). 
Melanin-Concentrating Hormone Receptors 
The original MCH receptor was an 'orphan' receptor dubbed 
SLC1 /GPR24, which was identified as the specific GPCR for MCH, and was 
called MCHR1 (Chambers, 1999; Lembo, 1999). MCHR1 is present in all 
mammals, with human MCHR1 being highly homologous with rodent MCHR1, 
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with a protein BLAST relationship of 96% identities and 98% positives, 
meaning that 98% of the amino acids in each protein have the same 
functionality, and 96% are exactly the same (Blast1 ) . After the discovery of 
MCHR1, it was determined that humans have a second MCH receptor which 
shares sequence homology with the core of MCHR1 (Hill et al., 2001; Mori et 
al., 2001 ) . Comparing the human MCHR1 with MCHR2, a protein BLAST 
showed that MCHR2 is comparable to 70% of MCHR1, with 37% identities 
within that region and 57% positives (Blast 2). 
Studies done in rats show that the MCHR1 acts as both a Gi- and a Gq­
coupled receptor. Stimulated cAMP was suppressed and a change was seen 
in intracellular calcium levels, both of which were caused by MCHR1 
activation (Hawes et al., 2000; Pissios et al., 2003). In contrast, MCHR2 is 
thought to be exclusiveiy coupied to the Gq pathway (Hiil et ai., 2001; 
Rodriguez et al., 2001 ) . As there are numerous tissues that MCH acts upon, 
from adipose to neural tissue, it is quite possible that this stimulation causes 
different effects on each tissue type, as it could activate different 
transcriptional and cellular changes in each type of cell. 
The majority of work performed studying MCHR1 has been performed 
in the brain. Effects of MCH include mood control and regulation of the 
voiding-reflex (Borowsky et al., 2002; Hegde et al., 2009). Very little work has 
been done to examine the effects of MCH on the peripheral tissues in the 
body. As mentioned previously, there are MCHR1 receptors in �-cells in the 
pancreas, and MCH treatment of those cells may cause changes in insulin 
production (Pissios et al. , 2003). Little is known about how MCH enters the 
blood, if it can cross the blood-brain barrier, or if it is produced from another 
source in the body. 
Desensitization to Melanin-Concentrating Hormone 
MCH causes a release of leptin in adipose tissue. Having a high level 
of leptin in the bloodstream reduces the ability to sense, in the brain, an 
increase caused by food consumption. Adipose cells would need to become 
unresponsive to MCH after the initial release of leptin to reduce the amount of 
leptin produced. As stated previously, there are a few methods that a cell can 
use to keep a receptor from continuously activating. These include: 1) 
degradation of hormone, 2) conformationally changing the receptor through 
modification or interaction with another protein, and 3) physical removal of the 
receptor from the membrane. G-protein receptor kinases, or GRK's, 
specifically phosphorylate the substrate bound form of the receptor. This 
phosphorylation increases affinity for inhibitory proteins, or arrestins, which 
inhibits further signaling by the receptor (Lefkowitz and Freedman, 1996). 
Additionally , interactions between and regulators of G protein-
signaling (RGS) cause a decrease in the activation of the receptor by 
essentially increasing the rate of GTP to GDP conversion by the G protein 
Vries et al., 2000). Interactions between specific RGS's and MCHR1 have 
been identified, and may also play a role in receptor desensitization. 
Specifically, RGS2 causes MCHR1 inhibition of the Gaq pathway and RGS8 
causes inhibition of the Gaito and Gaq pathways (Miyamoto-Matsubara et al., 
2010). There has been work done that has shown internalization of receptor 
after stimulation with MCH (Saito et al., 2004; Miyamoto-Matsubara et al., 
2010). !t \"las also shown that if clathrin-mediated endocytosis was inhibited, 
there was only partial inhibition of endocytosis, pointing to an alternative 
method of internalization (Saito et al., 2004). What is unclear, however, is the 
length of time MCHR1 is desensitized, and if endocytosis is truly the cause of 
desensitization, or if there is more involved in the process. 
Recent Advances in MCHR1 Signaling 
MCH causes a release of leptin from adipose cells, and as there is 
desensitization to the hormone over a period of time, it needs to be 
determined which of the possible mechanisms is causing desensitization. 
Desensitization work being done by our lab has shown that after an initial 
increase in activated ERK in response to treatment, there is not a similar 
response seen after a second treatment was administered thirty minutes later. 
As stated previously, work done by Saito et al. has shown that in response to 
MCH treatment, there is an internalization of the receptor via the clathrin­
mediated endocytosis pathway. They determined that there was 
internalization of 21.9% seen in as little as five minutes, and a greater 
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internalization rate of 44.2% seen after 30 minutes of treatment (Saito et al., 
2004). Attempts by our lab to replicate their internalization process have 
shown that internalization of receptor without overexpression of components 
in the clathrin pathway only occurs at 15 percent (Maden, 2012). This is 
contradictory, and may be because of the addition of arrestins and GRKs by 
Saito. If these parts of the clathrin pathway are not overexpressed, then our 
work shows that there is not a high level of internalization. Tetsuka et al. also 
looked at mutations in the C-tail of the receptor and the effect of these 
mutations on activation. They found that if certain phosphorylation sites 
(Arg319 or Lys420) on the tail were mutated, cellular signaling was attenuated 
(Tetsuka et al., 2004). 
Work performed by our lab showed that if one of the Arrestins (� 1 or 
�2) is co-expressed with the receptor, the internaiization rate increases 
dramatically up to 40 percent (Maden, 201 This points to an inefficient 
method of internalization via the clathrin-mediated endocytosis pathway. This 
leads to the hypothesis that clathrin-mediated endocytosis is not the way that 
desensitization to MCH is occurring. If the cells were using clathrin-mediated 
endocytosis only to desensitize MCHR1, it would be expected that without 
transfection of other proteins in the pathway, a significant amount of receptor 
would be removed from the membrane in direct response to hormone 
treatment. As mentioned previously, internalization can still occur if the 
clathrin pathway is inhibited. 
So, caveolins could be interacting with MCHR1 to desensitize signaling. 
This was substantiated by Cook et al. through isolation nf lipid rafts via 
sucrose gradient centrifugation. They showed that caveolin-1 and MCHR1 are 
co-localized within the lipid raft fractions. Additionally, MCHR1 
immunoprecipitates with caveolin-1, suggesting that caveolin-1 complexes 
with MCHR1 within the ce! !  (Cook et al., 2008). This interaction could be 
influencing the desensitization of MCHR1 after MCH treatment. Insulin 
receptors move into caveolae to facilitate efficient signaling, so it seems that 
MCHR1 could be using some sort of version of this to change its signaling 
reactivity (Gustavsson et al., 1999). Also, the receptor could be moving into 
the caveosome after activation at a lower rate than would be seen if the 
clathrin pathway was being used. The method of MCHR1 desensitization is 
unclear, and this thesis wiii attempt to answer some of these questions. 
Specific Aim 1 
Localization of MCHR1 within caveolae has been shown by Cook al. 
in CHO cells (Cook al., 2008). However, the isolations were performed in a 
singular cell type, with one method of isolation and utilizing an epitope tag to 
blot for the receptor. Modifying any these parameters could cause the 
receptor location to change, although it is hypothesized that the interaction 
between MCHR1 and caveolin-1 will be seen regardless of isolation 
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conditions. To further study this hypothesis, the following experiments were 
designed: 
1.  Multiple cell types will be examined to determine if lipid raft isolation 
with MCHR1 co-localization can be reproduced. 
The method of raft extraction will be examined through use of multiple 
lysing solutions with varying mechanisms for membrane perforation. 
3. Finally, the possibility that the epitope tag is influencing receptor 
localization will be addressed through isolation of the wild-type receptor. 
Specific Aim 2 
The dynamics of MCHR1 signaling and desensitization is still unclear. 
There are conflicting reports of the level of receptor internalization in response 
to agonist treatment, with prior work showing internalization occurs in small 
amounts (Moden, 2012). Addition of arrestins increases the amount of 
internalization, but they are highly expressed. It is hypothesized that there is 
very little internalization of the receptor. Additionally, the localization of 
receptor within caveolae may change in response to agonist administration or 
with the addition of the arrestins. The following experiments were devised to 
determine the validity of these hypotheses: 
1. Visualization of internalization of receptor will be attempted without the 
addition of the arrestins or GRKs to support the ._._,;\,J,.. data showing 
low internalization. 
2. Localization of the receptor on a sucrose gradient isolation will be 
examined before and after agonist administration to determine if 
receptor location within lipid rafts changes. 
3. The effect of addition of the arrestins will be determined through 
gradient isolations incorporating each arrestin individually to determine 
if the addition causes a change in receptor localization on the 
membrane. 
30 
Mat�rials & Methods 
Cell Culture 
Cell Lines and Passaging 
Three cell lines were used for this study. The first were CHO-K1 cells, 
or Chinese Hamster Ovary cells (ATCC), stably transfected with VSVg­
MCHR1 by Laurie B Cook. These cells were grown in F12K media (CellGro) 
containing 5% FBS (Atlanta Biological). The second cell line was Baby 
Hamster Kidney (ATCC) cells grown in DMEM (CellGro) and 10% FBS. 
Finally the last cell line was a pre-adipocyte 3T3L 1 cell line grown in 
DMEM+ 10% BCS (Atlanta Biological). All cells were passaged using trypsin 
EDTA (Thermo Scientific) and were passaged at 80-90% confluence for BHK 
and CHO lines and 50% confluence for 3T3-L 1 s. All cells were incubated at 
37° C, 90% humidity, and with 5% C02 maintained continuously. 
Differentiation of 1 s 
To differentiate s into full adipocytes, the cells were plated on 
1 Ocm dishes and allowed to grow to 80% confluency, with the media being 
changed as needed. On day O of differentiation, the cells were given 
DMEM+ 10%FBS +5% Penicillin/streptomycin (CellGro) containing 1:100 
Methlyisobutylxanthine (11.5mg/ml) (Acros Organix), 1:1000 Dexamethasone 
(0.4 mg/ml) (Sigma) and 1 :100 Insulin (1 mg/ml) for a final concentration of 1 O 
µg/ml (Sigma). On day 2 of differentiation, the cells were given 
DMEM+ 10%FBS +5% Pen/strep containing 1:100 Insulin, and on day 4 the 
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cells were given DMEM+ 10%FBS +5% Pen/strep containing 1 :400 Insulin for 
a final concentration of 4 µg/ml. On day 6 of differentiation, the cells were 
given DMEM+ 10%FBS +5% Pen/strep and allowed to grow until day 1 O when 
differentiation was complete. 
Cellular Transfection 
To insert desired DNA into the CHO-K1 and BHK-570 cell lines, 
LipoD293 (SignaGen) was used. The protocol recommended by SignaGen 
was followed, the media was changed 24 hours post transfection and 
experiments were run 48 hours post transfection. DNA concentrations for 
each of the plasmids used was 1 µg/ml. 
Fluorescent Microscopic Analysis 
lmmunocytochemistry 
Cells were plated on glass cover slips, and transfected with VSVg­
MCHR1 (From G.Milligan). After complete transfection 48 hours later, the 
cells were treated with Melanin-concentrating Hormone (American Peptide). 
To do this the media was aspirated off and one ml of DMEM- was added to 
each dish. After an hour the DMEM- was removed and one ml of 1 µm MCH 
solution was added to the dishes, which were allowed to sit for the desired 
time. The control plates were given new DMEM- instead of the MCH solution. 
The cells on cover slips were put on ice and the media aspirated. The cells 
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were washed twice with 2 ml of cold Phosphate Buffered Saline (PBS), 
treated with one ml of 4% Paraformaldehyde for 1 O minutes in PBS then 
washed three times with cold PBS. 
Humidifying chambers were made using glass Petri dishes, parafilm 
and damp paper towels. The cover slips were moved to the humidifying 
chamber and 250 µI of blocking buffer (of PBS \Nith 0.1 % Triton 
(BioReagents) and 5% Goat Serum) was added drop-wise to each cover slip. 
The coverslips were incubated for one hour, and then 250 µI primary antibody, 
rabbit VSVg-MCHR1 (Sigma) at 1:1000 concentration or mouse RAB7 (BO 
Biosciences) at 1:1000 concentration in blocking buffer was added to each 
cover slip and allowed to sit overnight at 4° C. After incubation, the solution 
was removed and the cover slips replaced in their dishes. Each cover slip 
was washed for five minutes with PBS a total of three times and rocked on an 
orbital shaker for the duration. The cover slips were then placed back in the 
humidifying chambers and 250 µI of secondary antibody, goat anti rabbit 
AlexaFluor 488 (lnvitrogen) at a 1 :5000 ratio, rabbit anti goat AlexaFluor 594 
(lnvitrogen), and DAPI (1.0µg/ml, Roche) at a 1 :5000 ratio, in blocking buffer 
was added to each cover slip and allowed to incubate for 45 minutes. The 
solution was removed and the slides transferred back to the dishes, and 
washed again for five minutes with PBS a total of three times on the orbital 
shaker. 
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The finished cover slips were mounted on slides using Prolong Gold 
(lnvitrogen) and clear nail polish was used to affix them to the slides. 
Microscopy 
Fluorescent microscopy was performed using a Zeiss Axiocam MRm 
fluorescence microscope with AxioVision imaging software. Image formatting 
was performed in Adobe Photoshop and assembled into figures in Microsoft 
PowerPoint. 
Cell Lysis for Caveolae Isolation 
Lysing 
For each gradient, two 1 Ocm dishes of the desired cell line were grown 
to a confluency of at least 80%, treated with 1 µM MCH for the desired time 
points, and then placed on ice. Each was quickly washed twice using 5 ml of 
different lysing solutions were used: 
1. Basic pH 1 1  Procedure: lysate is produced using 2 ml of 500 
mM Na2COs at a pH of 11. 
2. Neutral pH 7 Procedure: lysate is produced using 2ml of 
25mM TRIS and 250mM sucrose. 
Triton Procedure: lysate is produced using 2ml of MBS with 
1 % Triton at a cold temperature. 
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After the addition of the lysing solution to one of the two dishes, the 
cells were scraped off the dish using a squeegee, and the liquid transferred to 
the next dish. The scraping procedure was repeated for the second dish and 
then the solution was placed in a ?ml dounce homogenizer that had been 
chilled on ice, and 1 :1000 of protease inhibitor (Sigma) was added to each 
homogenizer. This solution was left to swell for 30 minutes. After swelling, the 
solution was homogenized 1 O times and allowed to swell for two minutes, 
after which this process was repeated 3 more times, for a total of 40 strokes. 
To the bottom of an ultracentrifuge tube (Beckman), two ml of the 
lysate was added, along with a 90% sucrose solution made in MES buffered 
saline (MBS; pH6.5, 25 mM Mes, 0.15 M NaCl). The tubes were then 
vortexed to thoroughly mix the lysate and the sucrose solution, making a 45% 
sucrose iayer. To the top of this iayer, 4 mi of 35% sucrose in MBS with 
250mM Na2C03 was carefully added. On top of the 35% sucrose layer, 4 ml 
of 5% sucrose in MBS with 250mM Na2C03 was added-ensuring no 
disturbance to the layer. Using a scale, two gradients were balanced to each 
other. The gradients were then placed on the SW41 rotor, and ultra­
centrifuged for 18 hours at 4° C at a speed of 39,000 rpm. The day after 
centrifugation, the tubes were removed from the buckets and one ml fractions 
were taken from the gradient, for a total of twelve fractions. The fractions were 
pulled from the top of the gradient right at the meniscus. The fractions were 
placed in microfuge tubes and frozen at -20°c. 
SOS-PAGE 
Gel Preparation 
SOS-PAGE gels were made according to the following chart. 
Table 1: Running Gel Recipes 
Running Gels 
10% Gel 12% Gel 
40% Bis-Acrylamide 2.5 ml 3.0 ml 
4X Tris-HCI /SDS �H 8.8 2.5 ml 2.5 ml 
10% APS 33 µl 33 µl 
dH20 5.0 ml 4.46 ml 
TE MED 6.6 µl 6.6 µl 
Table 2: Stacking Gel Recipes 
Stacking Gel 
4% Gel 
40% Bis-Acrylamide 488 µl 
4X Tris-HCI /SDS pH 
6.8 1.25 ml 
10% APS 25 µl 
dH20 3.21 ml 
TEMED 5.0 µl 
The desired fractions were removed from the freezer and allowed to thaw. 
sample, 100 µI was added a new microfuge tube, and to each 
was added 25 µI of 5X lamelli sample Buffer. The tubes were placed in a 
circular rack with caps placed on top and boiled for 2 minutes. They were 
removed and centrifuged at 13000 rpm for five minutes. The gels were placed 
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in the running apparatus and it was filled with 1 X Running Buffer. To the first 
well, 5 µI of EZRun ™ pre-stained rec protein ladder (Fisher) was added and 
then the samples were added subsequently. For the 12% gels, there was 5 µI 
of sample loaded to blot for Caveolin-1 and to the 10% gels; 15 µI of sample 
was loaded to blot for the VSVg-MCHR1 or MCHR1. After the samples were 
loaded, the gels vvere run at 100 V for about 70 minutes, or until the sample 
buff er reached the bottom of the gel. 
Semi-Dry Transfer 
After the gels were run, they were removed and placed in Towbins 
buffer (Appendix 1) for 1 O minutes. Along with the blot, two sponges (Bio Rad) 
and a nitrocellulose membrane (BioRad) of the same size were incubated. 
After incubation, the semi-dry transfer apparatus was set up so a sponge was 
on the bottom, followed by the membrane then the gel and then the final 
sponge. The top plate was placed over this, ensuring no bubbles and 
complete contact. The transfer was run at approximately 16V for 30 minutes, 
or until the ladder was no longer visible on the gel. 
Western Blot 
After the transfer, the nitrocellulose paper was placed in 5% Milk in 
(Appendix 1 ) . This blocking step occurred for 60 minutes, and after 
incubation 1 O ml of primary antibody in TBS-T was added for each specific 
blot. For both Caveolin-1 (BO Biosciences) and VSVg (Sigma), the primary 
antibody was made at a concentration of 1 
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in 5% milk in TBS-T. 
blots were allowed to incubate in primary antibody overnight. blots were 
washed three times for five minutes in TBS-T. After washing, the blots were 
incubated for one hour in secondary antibodies, both in goat-anti rabbit HRP 
(BioRad) conjugated at a concentration of 1 :5,000. The blots were then 
washed three times for five minutes each in TBS-T to remove excess 
secondary. A 1 :1 ratio from a Western Lightning™ Chemiluminescence 
Reagent Plus kit (Perkin Elmer) was used; the blots were incubated for one 
minute in the solution, wrapped in saran-wrap and taken to the dark room. 
The film (Kodak) was exposed to the blots for a range of times to achieve the 
best exposure, then developed (Kodak) for 30 seconds, fixed (Kodak) for a 
minute and then dried thoroughly. 
Bradford Analysis 
For each gradient, Bradford analysis was performed. In a 96-well plate, 
a standard curve was prepared with 20 µI Bovine Serum Albumin (BSA) (0-
100 µg) Biotech). To each well, 20 µI of each sample was added, and 
to all of the wells, 200 µI of the Bradford solution was added. entire 
experiment was run in duplicate, and the plate was read at 595 nm on the 
BioTek Synergy™ H1 Hybrid Reader plate reader and Gen 5 1.11 Software. 
Densitometry 
Using Adobe Photoshop, the desired blots were scanned in, converted 
to grayscale and inverted. The density was measured with a background 
reading used as the baseline. 
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Results 
Lipid raft isolation using CHO cells 
To determine possible changes of gradients performed in different cell 
types, a gradient was produced from Chinese Hamster Ovary cells. Chinese 
Hamster Ovary cells that had previously been stably transfected with VSVg­
MCHR1 by Laurie B. Cook were lysed and a sucrose gradient was performed 
using a detergent-free isolation method with a pH of 11, as previously 
published (Cook et al. ,  2008). The isolated fractions were run on a 12% SDS­
PAGE gel and after transferring the proteins on the gel to nitrocellulose paper, 
the nitrocellulose was cut below the 40-kDa molecular weight marker. A 
'vvestern blot was then pertormed on each half of the membrane, the top half 
was blotted for VSVg-MCHR1 and the bottom half for caveolin-1 (Figure 6) . 
The a-VSVg blot showed bands localized to fractions 4, 5 and 6 at the 
molecular weight of approximately 55 kDa (Figure 6A) . The band at fraction 4 
contains the highest density of protein compared to the other two bands. For 
the a-caveolin-1 western blot, there was a large quantity of caveolin seen in 
fractions 4, 5, and 6 with a molecular weight of approximately 24 kDa (Figure 
68) . The caveolin in fractions 4 and 5 has a higher molecular weight band 
nearer to 50 kDa, possibly representing an oligomerized set of caveolin with 
the lipid raft. There was a smaller amount of caveolin present in fractions 3, 
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9 and 12. The localization of caveolin-1 and MCHR1 to fractions 4 and 5 is 
consistent with the previously published work, performed in this lab (Cook et 
al., 2008). 
Isolation of lipid rafts using alternative lysing methods 
While the detergent-free basic pH isolation method has been 
successful in isolating caveolae and has shown a co-localization between 
caveolae and MCHR1, there are other methods of isolating caveolae from the 
lipid membrane (Hooper, 1999). If only one method is examined, such as the 
previously described basic pH method, there is a possibility that the lysing 
solution, specifically the high pH, is the cause of the co-localization between 
receptor and lipid raft. Therefore, multiple methods were examined to verify 
that the isolation method does not affect localization of receptor on the 
gradient. To do this, current literature was reviewed and two other lysing 
methods were discovered. first involved a lysing solution that contained 
1 % Triton in MBS performed at 4°C, utilizing the non-ionic detergent to lyse 
the cellular membranes. The second contained 250mM Sucrose in a TR IS 
buffer-using a slight osmotic gradient to help lyse the cells (Liu al. , 1998). 
The TritonX-100 method was used because lipid rafts are known to be 
detergent insoluble at very cold temperatures, so they will remain 
structurally intact after isolation (Macdonald and Pike, 2005). second was 
used as a simple membrane disruptor, with the lipid rafts being held intact by 
high density of lightweight lipids, and it has been proposed that the 
glycosphingolipids form hydrogen bonds to further stabilize the membrane 
(Anderson, 1998). These two experiments were performed using the 
transfected Baby Hamster Kidney (BHK) cell model, to obtain a high level of 
VSVg-MCHR1 within the cells. If MCHR1 is truly localized within caveolae, 
then the isolation method will not change the co-localization. 
The gradients were performed for each method, and twelve fractions 
were isolated. Lysate from each of the gradients was also kept to determine 
overall protein concentration from the lysing of the cells. The fractions were 
run on 10% SOS-PAGE gels to determine the distribution of receptor, and on 
12% SOS-PAGE gels to determine the distribution of caveolin 1. The two 
different densities were used to ensure that the smaller caveolin molecule did 
not run off of the gel, and so that both gels could be run at the same rate. 
Additionai iy, by not cutting the biot, a i i  of the avaiiabie protein could be 
visualized.  
The corresponding blots were treated with either a-VSVg antibody or 
a-caveolin 1 antibody. In both new isolation methods, distribution 
caveolin is less localized than when using the basic pH detergent-free 
isolation method (Figure 7 A&B). In both cases, instead of having a large 
amount of caveolin in fractions 4-6 ,  as seen in the CHO isolation (Figure 68) ,  
there is caveolin present from fraction 4 to the bottom of the gradient. For the 
neutral isolation, there is a slight increase in the density of the bands for 
fractions 4 and The distribution of the receptor changed as well, with more 
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of VSVg-MCHR1 present at the bottom of the gradient (Figure 7 A&B). The 
band weights for VSVg also changed, with a band at approximately 48 
kDa present in fractions 4 and 5, and large molecular weight bands 
corresponding to a 75-80 kDa which could possibly be a dimerized version of 
the receptor. In fractions 10-12, there are lower weight bands around 30 kDa 
that could correspond to a cleaved form of MCHR1 within the ce! ! .  
Interestingly, the density of the VSVg-MCHR1 blot follows the 
distribution seen in the caveolin-1 blots, even appearing to be in a density 
proportional to the amount of caveolin. This supports the previously published 
results by our lab, where there is a co-localization between caveolin-1 location 
and VSVg-MCHR1 location (Cook et al., 2008). To analyze this association, 
densitometry was performed that showed corresponding increases and 
decreases in the density of the fractions when comparing caveoiin to MCHRi 
(Figure 7C&D). Bradford analysis of both of the gradients shows that there is 
little overall protein at the top of the gradients, and that at fraction 5 there is 
which 
the bottom of both gradients (Figure 8). 
This relationship supports the hypothesis that there is an interaction 
between caveolin-1 and MCHR1. While these methods of isolation are not as 
successful in isolating lipid rafts as the basic pH isolation method, they do 
show a correlation between the presence of caveolin 1 and VSVg-MCHRi .  
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For this reason, the lysing procedure that used the detergent-free basic 
pH solution was used in future experiments. 
Distribution of MCHR1 without an Epitope Tag 
In order to continue to determine the effect of co-localization of MCHR1 
to caveolae, the receptor was studied without the VSVg epitope tag. While it 
is easier to blot for the receptor with the epitope tag, it could influence the 
placement of receptor on the membrane. Adding an epitope tag to a targeted 
molecule allows for easy targeting of the desired protein. Antibody quality and 
purity are better for epitope tags, as they are used quite often to label proteins 
that lack quality antibodies. To complete the gradient, BHK cells were 
transfected with MCHR1 without the VSVg tag, and a basic pH detergent-free 
sucrose gradient isolation was performed. The twelve fractions obtained after 
centrifugation were run on a 10% SOS-PAGE gel to blot for receptor and a 
12% SOS-PAGE gel to blot for caveolin-1. 
Caveolin distribution is at the highest density in fractions 4 ,  5 and 6 at a 
molecular weight of approximately 24 kDa (Figure 9A). MCHR1 distribution is 
from fraction 4 to the bottom of the gradient, but there is a density increase 
seen in fractions 5 and 6 .  As with the blots seen for the different lysing 
solutions (Figure 7 A&B), there are multiple bands of MCHR1 present in each 
fraction. The lowest molecular weight marker is present in only fractions 5 and 
6,  and corresponds to a molecular weight of approximately 44 kDa. In the rest 
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Fraction Number 
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of the fractions, there are bands corresponding to a molecular weight of 
approximately 50 kDa, with higher weight smears above all the fractions. 
Bradford analysis shows that there is little protein at the top of the 
gradient, and fractions 4-6 contain 33% of the total protein (Figure 9B). 
There is a decrease in protein for fractions 6 and 7, then the largest amount of 
protein from fractions 9-12-a total of 49% for those fractions. 
Determination of internalization of MCHR1 
Initially, work was performed to determine the end location of receptor 
internalization. This was studied by staining BHK cells for the receptor and 
one of the Rab proteins. Two Rab proteins were studied, Rab5 and Rab?, 
Rab5 is known to associate with early endonucleases and Rab 7 with late 
endonucleases (Stenmark et al., 1995; Bucci et al., 2000). These experiments 
were not successful, however, due to poor staining of the receptor. Very few 
changes in distribution were seen in response to treatment, even with the 
inefficient staining. This indicated that the internalization of the receptor 
needed to be studied more directly. 
To determine if internalization could be visualized, overall expression 
of receptor was studied in a BHK model system over varying hormonal 
treatments. To do this, cells were transfected with VSVg-tagged MCHR1 and 
then plated onto cover slips; the VSVg tag was used due to the higher quality 
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antibody for VSVg over that of MCHR1. The transfected BHK cells were 
treated with 1 µM MCH in DMEM- for either 0, 30 or 60 minutes. The control 
group of no treatment (0 time point) was given DMEM- for 60 minutes. They 
were then fixed and stained using fluorescent antibodies to mark VSVg­
MCHR1. Cells were observed (Figure 10) to have a widespread distribution of 
VSVg; with slightly higher localization near the nucleus. The distribution 
visualized does not clarify whether the receptor is within the cytosol or on the 
membrane. There was visually little difference in receptor distribution between 
the various treatment times, and no distinct internalization of the receptor from 
the membrane. There is no concrete internalization seen, unlike systems that 
have co-transfection with arrestins. This low internalization is substantiated by 
the internalization seen in the ELISA data performed by our lab, and showed 
U1at there was intemaiization of receptor of 15 percent (Maden, 2012). 
Effect of treatment with MCH on localization of MCHR1 to Caveolae 
As previously described (Figure 10), there does not seem to be 
internalization of receptor due to MCH treatment. In addition, co-localization 
between MCHR1 and caveolin-1 has been verified using multiple isolation 
methods. It is possible that the interaction between the receptor and caveolin-
1 is the cause of receptor desensitization. determine if there is a change in 
receptor localization on the membrane due to hormone treatment, cells 
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were transfected with VSVg-MCHR1. One set was treated for thirty minutes 
with 1 OOnM Melanin-Concentrating Hormone in serum free media, and the 
other was given serum free media as a control. The cells were lysed using the 
detergent-free basic pH isolation method, in collaboration with 
Laurie B. Cook. The isolated fractions were run using a 10% SOS-PAGE gel 
for the VSVg-MCHR1 blot and a 12% SOS-PAGE gel for the caveolin-1 blot. 
Both blots were treated with the VSVg antibody and the caveolin-1 antibody 
correspondingly. 
For the caveolin-1 blots, there were distinct bands seen in fractions 4 
and 5 in each blot (Figure 11 A). Trial run 1 shows more caveolin-1 in the 
lower fractions, but this can be attributed to the pipetting during production of 
that sucrose gradient. For the VSVg blots, there is a greater density seen in 
fractions 4 and 5 (Figure i 1 A), with the muitipie higher molecular weight 
bands seen in previous blots (Figure 7 A and Figure 11 A). For each of the 
gradients, there is a distribution of VSVg across the bottom of the gradient. 
could be receptor being produced or those in transport to membrane, 
but it does not seem to be highly associated with caveolin-1. 
There seems to be a MW shift in the upper band of the VSVg-MCHR1 
blot that corresponds with the treatment of hormone, as depicted in the 
turquoise boxes (Figure 11 A). There appears to be a change in the 
distribution of the receptor smear above 50kDa in weight. These blots suggest 
that some of the receptor is disappearing from this high molecular weight. 
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This could be caused by a change in the receptor, either a dimerization loss 
or a modification due to phosphorylation or ubiquitination. 
Bradford analysis shows that there is little protein in the top of the 
gradients, with concentration increasing at fractions 4 and 5, decreasing 
through fractions 6 to 8 and then increasing again to the highest levels at the 
bottom of the gradient, as is normal for a !ipid raft isolation (Figure 11 B). In 
response to treatment of MCH, there is no visible change in localization of 
receptor within lipid rafts. This means that it  is not the transition of receptor in 
to or out of lipid rafts that is causing the desensitization, as it is not occurring. 
Desensitization could occur though one of the other methods previously 
mentioned, such as receptor modification, which is suggested by the MW shift 
seen in these blots. What exactly is happening is unclear, however, and more 
work must be done. 
Effect of {J-Arrestin co-expression on localization of MCHR1 
further examine the dynamics of MCHR1 and caveolin-1 interaction, 
the effect of arrestin expression was studied. Work performed by our lab 
shows that there is a decrease in the surface expression of receptor if �­
Arrestin 1 is present, and that both of the arrestins cause a greater increase 
in the internalization of MCHR1 (Moden, 201 It was theorized that if the 
addition the arrestins caused internalization, they might affect the 
interaction of caveolin-1 and MCHR1. 
In order to determine the effects the arrestins had on gradient location 
of MCHR1, BHK cells were transfected with VSVg-MCHR1 and either 
pCDNA3 (as a control for the arrestin plasmids), fj-Arrestin 1 or f3-Arrestin 2. 
The cells were treated with either 1 OOnM MCH in serum free media, or serum 
free media as a control, and then the cells were lysed using the basic pH 
detergent-free method. Initially, the collected fractions \J\Jere pooled to reduce 
the number of western blots that had to be performed. This pooling was 
performed by combining fractions 1 to 3, fractions 4 to 6 ,  fractions 7 to 9 and 
finally fractions 1 O to 12. Western blots were performed for caveolin 1 and 
VSVg-MCHR1 as previously described. To look at the specific changes 
between the treated and untreated gradients, untreated and treated pooled 
fractions were run side-by-side. There is no protein in the top pooled fraction, 
and very iittie in the bottom two pooied fractions, so these were omitted. 
In the pooled fraction containing fractions 4-6, there is an increase in 
the amount of caveolin-1 and in the VSVg-MCHR1 (Figure 12). There is much 
more receptor displayed in the pCDNA3 isolations, with less for each of the f3-
Arrestins. Each of the VSVg blots show the three distinct weight bands as 
described previously. What is clearer here, however, is the change in the 
density of the upper weight of the VSVg-MCHR1 (Figure 13). is less 
protein in the upper band after treatment, which is approximately at 80 kDa. 
There is also a shift up of about 10 kDa from untreated to treated cells 
(depicted by the turquoise lines), possibly signifying a modification of 
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MCHR1 -possibly a phosphorylation of the receptor. Bradford analysis shows 
that there is the same amount of protein in each of the gradients and that 
each gradient follows the normal isolation amounts for isolation of caveolae at 
fractions 4 and 5 (Figure 14)" 
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Hormonal regulation of metabolism and satiety is a complex system 
that has many inputs and feedback system. Understanding each step of this 
path is very important, as it can provide possibilities for hormonal treatment of 
obesity. One of these hormones is melanin-concentrating hormone. Most of 
the current literature on MCH focuses on its effects in the brain, and few 
studies are performed in peripheral tissues. This thesis focuses on MCH and 
its receptor MCHR1 and the dynamic regulation of receptor function and 
desensitization. 
Lipid raft isolation using CHO cells 
Lipid raft domains are known to be detergent insoluble due to high 
levels of cholesterol, GPl-anchored proteins and glycosphingolipids (Hooper, 
1999). The presence of these lighter weight lipids causes the lipid raft 
sections of the membrane to be isolated from the rest of the membrane via a 
sucrose density gradient (Smart, 1995). Various lysing methods can be used 
to isolate caveolae from the membrane, and each varies in the solution used 
to lyse the cells (Liu, 1998). Song et al. showed that a sodium carbonate 
void of was effective isolating Gi2a and G�v co-
localize with caveolae (Song, 1996). Prior work performed by our lab showed 
that MCHR1 was localized within caveolae while clathrin was at the bottom of 
gradient (Cook, 2008). 
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In order to determine whether the detergent-free isolation could again 
be performed successfully, stable CHO-K1 cells were lysed and lipid rafts 
were isolated. As seen from the blots (Figure 3) , there is normal distribution of 
caveolin-1 and a corresponding distribution for VSVg-MCHR-1, with 
enrichment occurring in fractions 4 and 5 ,  as was published by our lab and 
also observed by Song et al. in their aforementioned work (Song et al. ,  1996). 
Bradford analysis shows that there is a small increase in the amount of 
protein in these fractions, but that the majority of the protein in the gradient is 
at the bottom. This implies that the floating of the lipid rafts is not due simply 
to a large amount of protein at fractions 4 and 5 ,  but in fact due to successful 
isolation of the lipid raft domains from the rest of the cellular debris. 
Isolation of iipid rafts using aiternative iysing methods 
As mentioned previously, isolation of lipid rafts can be performed in a 
few different ways. The original method used was the detergent-free basic pH 
isolation as reported by Cook and Song (Song, 1996 ; Cook, 2008). It is 
conceivable, however, that isolation of the receptor to the lipid rafts was 
caused by the lysing method due to molecular changes caused by the lysing 
solution (Anderson, 1998).The insulin receptor is co-localized with caveolae 
when isolated with the basic pH method, but that localization is lost when the 
isolation is performed with detergents (Gustavsson et al., 1999). It is theorized 
that the method of membrane perforation could cause molecules to 
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unintentionally cluster with the impermeable lipid rafts, causing unnatural co­
localization (Mayor and Maxfield, 1995). Triton X-100 addition to free-floating 
lipids causes them to aggregate and form micelles, suggesting that the 
addition of the detergent to the membrane may cause aggregation of lipids 
(Heerklotz, 2002). As there are pros and cons to each isolation method, more 
than one must be examined to determine the extent of co-localization. 
The two other methods used were a detergent isolation using Triton X-
100 and a different detergent-free isolation using an osmotic gradient created 
with sucrose for lysis, both previously reported by Liu et al. and Smart et al. 
(Smart , 1995; Liu , 1998). The Triton X-100 isolation was performed in a cold 
room and on ice to get the coldest temperature possible, as this helps to 
maintain the stability of the lipid rafts. Triton X-100 isolates lipid rafts best 
when at a 4° C temperature, whiie at 37° C the isoiation becomes imperfect 
(Brown and Rose, 1992). As can be seen from the gradients, the distribution 
of caveolin-1 along the gradient is much greater in both methods of isolation 
then seen in the CHO cell isolation (Figure There are a few reasons for 
this, for the Triton X-100 isolation, it is imaginable that the gradients and cells 
were not kept cold enough. If the cells were not kept at the optimum 4°C, the 
stability of the lipid rafts would have been compromised. In the case of the 
osmotic isolation, there was already sucrose in the lysing solution. This could 
have caused a change in the densities of the gradient, and changed the 
distribution of the caveolin-1. Also, the lysing procedure could have been less 
effective as the only method of isolation was through a slight osmotic gradient 
and pulverization. Despite the inefficient isolation of caveolae, it appears that 
there is a correlation between the amount of caveolin-1 and VSVg-MCHR-1. 
Isolating caveolae via Triton X-1 00 is more delicate than other methods, 
and the molecules that are maintained within the domains via this method can 
vary and can depend on the amount and type of detergent present (Pike, 
2003) . It is possible that for the detergent isolation, too much detergent was 
used, which compromised the isolation abilities. Isolations done isolating Ras 
with caveolin-1 showed high amounts of Ras and cav-1 at fractions 4/5 with a 
slight amount of protein from fraction 8 to the bottom of the gradient (Kawabe 
et aL , 2001 ) . Also, isolations performed on matrix-metaloproteases (MMP's) 
showed similar distribution of both the MMP's and caveolin-1, with slightly 
more of each at the bottom of the gradient (B et al., 2001 ). These are 
comparable to the originally performed CHO-K1 isolations (Figure 3) , and to 
the previously published work performed using the basic pH solutions (Cook 
et al., 2008) . gradients performed here, however, show greater 
distribution of both caveolin-1 and receptor across the bottom of the gradient 
(Figure 4) , and the isolation methods were not as exact as hoped. 
The isolations show that there is a correlation between the density and 
localization of caveolin-1 and VSVg-MCHR-1. The detergent-free basic pH 
isolation method previously published seems to be the best at maintaining the 
caveolae structure for proper isolation (Cook et al. , 2008) .  The correlation 
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between receptor amount and caveolin is maintained for each isolation 
method, but the type of lipid rafts isolated through the basic isolation method 
are the most defined. 
Verification of distribution of untagged MCHR- 1 
It is conceivable that adding the VSVg tag to MCHR1 causes a change 
in the localization of the receptor on the membrane. To further investigate this 
potentiality, a western blot was performed for MCHR1 without the VSVg tag. 
Epitope tagging was performed by genetically inserting a well-characterized 
antigen into a plasmid of the desired protein. During transfection, the tag was 
added onto the desired molecule (in this case MCHR1) and provided an easy 
way to target for the molecule. While the VSVg tag is small-11 amino acids 
in size-it couid interact with surrounding moiecuies on the membrane 
surface. Epitope tags have been used previously due to the higher quality of 
the antibody for the VSVg molecule in comparison to the MCHR-1 antibody. If 
the blots for VSVg and MCHR1 are compared (Figure 11 and Figure 9), it can 
be seen that the background of the MCHR1 blot is dirtier. Numerous attempts 
were run of the MCHR1 blot, and the one reported showed the best antibody 
blotting. The correlation seen in these blots show that there is co-localization 
between MCHR-1 and caveolin-1. This interaction is present regardless of the 
type of isolation, or the tag that is placed on the receptor. 
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Determination of internalization rate of MCHR 1 
I n  o rder to determine the i nternal izat ion of MCHR1  after agon ist 
treatment ,  f luorescent microscopy was performed . After analysis of the 
d istribut ion of MCHR1  over the cel l  surface at g iven treatment t imes , very l ittle 
internal izat ion is seen (F igu re 1 0) .  There is uniform d istribution across the 
entirety of the membrane and the cytoso l ,  with s l ightly h igher concentration 
around the nucleus, possibly i n  the E R  or  Golg i .  Th is d istribution has also 
been seen for other receptors such as insu l in  in ad ipose and P2X receptors in 
neurons (Khakh , 200 1 ; Hunker, 2006) . After treatment, however ,  there is l ittle 
d ifference in the d istribut ion of the receptor .  The same patterns are seen after 
1 O and even 60 minutes of 1 µM M C H  treatment .  This treatment amount was 
used to ensure that complete saturation of the receptor was ach ieved . The Kd 
of M C H R 1  is 3 . 1  ± 0.4 n M ,  and th is experiment was performed i n  an 
overexpression model , so by treati ng with 1 µM MCH complete saturation was 
ensured (An , 2001 ) .  
Th is lack of i nternal ization i s  i n  contrast t o  work performed by Saito et 
al. who determined that there was internal izat ion of . 9% seen in as l itt le as 
five m inutes , and a greater internal izat ion rate of seen after 30 minutes 
of treatment (Saito , 2004) . Past work performed by Katr ina Haude ,  an 
undergraduate in  our  lab ,  shows that i f  either �-Arrestin is i ncluded in 
transfect ion ,  there is an internal ization of receptor from the membrane (F igure 
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1 5) (Maden,  20 1 2) . By comparing th is marked i nternal izat ion with the resu lts 
provided of MCHR1  i nternal izat ion (F igu re 1 0) ,  it can be seen that if there are 
no add it ional parts of the clathri n pathway added , i nternal ization does not 
visibly occur .  Th is does not mean that there is not i nternal ization ,  however,  as 
there cou ld be very low internal izat ion that cannot be visual ized . Using 
fluorescent m icroscopy i n  th is way would not show other changes occurr ing  
on the membrane. As  th i s  is a transfected receptor mode l ,  there cou ld be an  
overwhelm ing amount o f  receptor on the  membrane, and  so  the  sheer 
number of receptors present wou ld  cause the movement of receptors on the 
membrane or  i nteract ions between receptors to change. 
Effect of treatment with MCH on localization of MCHR- 1 to caveolae 
If desens it ization is caused by interact ions with caveolae ,  the effect of 
treatment with M C H  on local ization with i n  l ip id rafts must be examined . After 
analysis of the g radients, there is l ittle change in the overal l location of 
receptor with i n  caveolae (Figu re 1 1  ) . is not unusual . There are examples 
l ike the EGF and PGDF receptors that are associated with caveolae without 
agonist ,  but after agonist add it ion are on ly transiently associated (Matveev 
and Smart, 2002) . Another examp le is the angiotensin I I  type 1 A receptor (a 
Gaq GPCR) wh ich is associated with caveolae regard less of agon ist add it ion 
( lsh izaka et a l . ,  1 998) . This lack of change in the local izat ion of receptor 
with i n  l ip id rafts may mean that i nternal izat ion is not the reason that there is 
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desensitization occurring with M C H R i , possib ly supported by the results of 
the f luorescent images reported earl ier ( Figure 1 0) .  
There have been reports o f  i nternal izat ion o f  caveolae t o  either 
endosomes or to an i nternal structure known as a caveosome. Work done 
looking as low-density l ipoprote ins u ndergoing transcytosis across endothel ial 
cel ls  showed that the LDL's crossed through the caveosome structures 
through caveolae endocytosis (Candela et al . ,  2008) . So if there is the same 
level of LDL's in  the caveosome as in the membrane caveolae, the 
caveosome should be approximately the same weight as membrane domains. 
If there was i nternal ization  to a caveosome,  there is the potential that 
the smal l  amount of receptor i nternal ized cou ld not be visual ized i n  the 
fluorescent i mages (F igu re 1 0) .  While caveosomes are large structures, there 
wou ld  h ave to be a large quantity of i nternai ized receptors to visual ize the 
caveosome. Pre l im inary work done by our lab using confocal and electron 
m icroscopy performed on d ifferent iated 3T3L 1 cel ls showed large vesicu lar 
bodies that cou ld  have been large membrane caveolae or even i nternalized 
caveolae. It is  imaginable that there are i nternal caveosomes shutt l i ng 
caveolae and receptors to and from the membrane, and that the activated 
receptor is removed from the membrane via th is pathway, but that it cou l d  not 
be visual ized due to the low amount of i nternal izat ion .  I t  is also l i kely that 
there is  a conformational change occurring of the receptor with i n  the l ipid rafts . 
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This change cou ld be switch ing off the activity of the receptor wh i le 
maintain ing the overal l concentrations with in caveolae .  
Effect o f  /J-Arrestin co-expression o n  localization o f  MCHR- 1 
Work done previously by Katrina  Haude shows that there is visual 
internal ization due to M C H  treatment when one of the J3-Arrestins is 
incorporated into the cel l u lar model (F igure 1 4) (Mode n ,  20 1 2) . So the effect 
that t ransfect ion with either J3-Arrestin  1 or J3-Arrestin2  has on the co­
local ization of receptor to l ip id rafts was stud ied. As was seen in the western 
blots , there is a decrease of the receptor seen when an arrest in is 
incorporated (F igu re 1 2) .  This is interest ing ,  as there is sti l l  normal expression 
with the pCDNA3 transfection ,  and as the Bradford analysis of each set of 
fract ions is essential ly the same. 
So there is some sort of h indrance occurring when the arrestins are 
present i n  the packag ing of receptor with in  the l i pid rafts , o r  there is a change 
in  the activity of the receptor with arrest ins ,  requ i ri ng less receptor to be 
present. When comparing th is i nformation with work performed by Jay Maden 
using EL ISA analysis of surface expression of receptor,  there are some 
corre lat ions. When the cel ls  were transfected with J3-Arrest in 1 , there was less 
receptor visual ized on the external surface of the receptor .  This corresponds 
to the decreased expression seen on the �-Arrestin  1 g radient ,  and so there 
may be some h indrance occurr ing due to the arrestin  recru itment, less 
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transfect ion of the receptor itself or even more degradation of the receptor 
due to the p resence of the arrestin .  I n  the instance of cel l  surface expression 
for (3-Arrestin 2, there was approximately the same amount of receptor seen 
as for the pCDNA3 model .  Th is cou ld s ignal a better relat ionship between 
MCHR- 1  and (3-Arrest in 2 ,  a theory that has been studied previously by Evans 
et al. They reported that i n  cel ls vvere tr iple-transfected with tagged-MCH R1 , 
GRK2 and either (3-arrest in 1 or 2 .  I n  the cel ls  expressing (3-arrest in 2 ,  there 
was selective recruitment to the p lasma membrane .  This association with 
receptor was transient, and i nternal izat ion of both (3-Arrestin 2 and the 
receptor i n  conjunct ion did not occur ( Evans et al . ,  2001 ) . I t  is important to 
note that their work was performed with GRK,  and experiments done by our  
lab  d id not h ave th is  trip le-transfection protocol ,  and transfect ion with either (3-
Arrest in showed internal izat ion.  When neither of the  arrest ins are present, 
however,  there is increased expression seen throughout the g radient and co­
localizat ion with caveolae is more pronounced . 
Internalization of upper weight MCHR1 due MCH treatment 
Whi le analyzing the western b lots comparing treated cel ls  with 
untreated cel ls ,  a pattern emerged . Before treatment, the VSVg-MCH R- 1  
western b lots showed a band with a molecular weight at around 40  kDa, and 
this wou ld be the receptor without any modification or d imerization .  The 
known molecular weight for MCHR1  is at 46 kDa, which is the largest density 
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band seen on the western b lots , concurring with the normal s ize of the protei n  
(Bittencourt e t  al . ,  1 992) .  The  s l ight d ifference i n  size cou ld  be due  to  the gel 
run ,  with possible variations in the segregation .  Above th is weight is a smear 
that goes to the top of the grad ient ,  which cou ld be composed of d imers or 
even ol igomers of MCH R 1 . Work performed using Fluorescence Resonance 
Energy Transfer (FRET) of f luorescently tagged lutein izing hormone has 
shown that on  the cel lu lar surface , FRET has been detected between mu lt ip le 
hormone bound lutein iz ing hormone receptors . This suggests that the LH 
receptor is a functional d imer on  the cel l u lar surface. I nterest ing ly, FRET was 
dependent o n  the receptor's s ignal ing potential , with no FRET seen with 
mutant receptors , s ignifying  that active receptors need to interact to be 
funct ional (Roess, 2000) . With in  the Tumor-Necrosis Factor-a fami ly, it is 
bel ieved that agon ist-promoted d imerization forms an equ i l ib ri um ,  wh ich is 
thought to be an important step in receptor activat ion and deactivat ion (Weiss 
and Sch lessinger,  1 998 ; Sch lessinger,  2000) . I f  this activat ion/i nactivation 
equ i l ib ri um is true for MCH R 1 , than the loss of the upper weight d imer after  
treatment wou ld mean that the active form of  the receptor is a d imer or even 
an o l igomer, as the h ighest weight band is more then double the 46 kDa 
weight of the single receptor. 
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Mode of Receptor Desensitization Theory 
For a receptor to be desensitized,  there must be a lack of active 
receptor on the membrane. As mentioned previously, there are d ifferent ways 
that cel ls acco mpl ish th is task. This thesis considers two possible methods of 
desensitization .  F i rst, the receptor could be modified to become u nresponsive 
to hormone treatment .  Second,  the receptor cou ld  be removed from the 
membrane through an endocytosis method . Work done by our lab showed 
that MCH treatment causes an increase in activated E RK,  and that after a 
second treatment th i rty minutes later there was not the same rate of activation 
(F igure 1 6) .  I nit ial ly ,  it was thought that i nternal izat ion of the receptor via the 
clathr in pathway was the cause for th is long period of desensitization , as 
proposed by Saito et al. (Saito , 2004) . Work shown by f luorescent imag ing in  
th is  report and EUSA data reported by jay Maden (F igu re 1 7) ,  however, 
showed that without transfection with parts of the c lathrin pathway, there is 
not a large percentage of internal ization seen in response to MCH treatment. 
This means that there cou ld an alternative way in  which the cel l  is 
desensit izing to hormonal stimu lation .  The proposed alternative is through co­
localizat ion and i nteract ion with caveolae. Th is i nteract ion was present 
despite the method of isolation or the tag associated with the receptor. If part 
of the arrestin pathway is  added , then a g reater i nternal izat ion is seen ,  but i n  
the case of B-Arresti n  1 there i s  less receptor seen on  the surface . 
Add it ional ly, stud ies performed looking at co-local ization before and after 
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hormone treatment showed that there is a loss of an upper-weight band of the 
receptor ,  and a possible phosphorylat ion event is occurring (Figu re 1 3) .  No 
other lab has publ ished work showing a phosphorylated form of MCHR1 , so 
th is cou ld be an excit ing development. I t  cou ld  relate to the work showing 
inactivat ion of the receptor if certain amino acids are deleted , as d iscussed 
previously (Tetsuka et al . ,  2004) . If these are taken in conjunction ,  it can be 
theorized that M C H R 1  is local ized to caveolae and that some interaction 
occurring with in  caveolae is causing desensitization . 
Caveol in - 1  can interact with receptors with in caveolae by complexing 
with the molecule ,  and then d issociate when the receptor is activated .  If th is is 
the case for MCH R 1 , then the reactive form of the receptor cou ld be 
d issociat ing from caveolae after activat ion .  Th is i nteraction was publ ished by 
our  iab through i m munoprecip itat ion experiments showing that caveoi i n- i  and 
MCHR1  immunoprecip itate in conjunction with o ne another (Cook et al . ,  2008) . 
If th is is taken in  combinat ion with the EL ISA data showing that there is 
rough ly 1 5% internal izat ion , then it can theorized that the d issociated 
receptor is i nternal iz ing .  If parts of the arrestins  are included in th is theory, 
then the associat ion between the arrest ins and the receptor could  be more 
readi ly pu l l i ng the active receptor out of caveolae and internal iz ing it . This  
idea was d iscussed previously in  re lat ion to  the  insu l in  receptor and  its 
movement into and out of caveolae, with s ignal i ng on ly occurring when the 
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receptor is  with in  caveolae (Gustavsso n  et al . ,  1 999) . A s imi lar process could 
be occurring with MCHR1  and movement with caveolae .  
I nteresting ly, work performed by Robert Carro l l  working with an RNAi 
for caveol in - 1  and looking at leptin production in response to MCH stimu lation , 
showed that if caveol in - 1  is depleted , then there is a greater production of 
leptin .  Combining th is with the theory that d imers or o l igomers of the receptor 
are the active form of the receptor ,  then it is conceivable that the receptor 
i nteractio n  with caveol in - 1  is caus ing less of the active d imer to be avai lable. 
If caveol i n - 1  is removed , then th is h indrance d isappears , and there are more 
d imers formed and more lept in  produced i n  response to MCH t reatment .  
How cou ld th is  al l  add u p  to desensitization? I n  summary, co­
loca l izatio n  with caveolae could  cause there to be fewer of the d imerized 
receptor avai iabie on the membrane .  After activation ,  these d imerized 
receptors may d issociate from caveol i n - 1  and be removed from the 
membrane , or d issociate from one another ,  becoming inactive i n  response to 
MCH treatment. The interaction between caveol in - 1  and MCH R 1  cou ld 
potentia l ly i nh ibit the formation of  new d imers ,  and so possib ly contribute to 
the t ime requ i red to re-sensitize . This could explain why signal ing occurs at a 
larger rate without caveol in - 1  . 
Future Directions 
To further verify the proposed method of desensit ization ,  there are a 
few key experiments that cou ld  be performed . Caveo l i n - 1  does interact with 
MCHR1 , so it should be determined whether d imers of M C H R 1  form and if 
they are the active form of the receptor.  This cou ld be done us ing FRET 
analysis , tagg ing MCH with various f luorescent prote ins ,  such as Cyan­
fl uorescent protei n  and Yel low-f luorescent protein ,  and determin ing if there is 
FRET seen between two receptors on the membrane, as p reviously described 
in the Lute in iz ing Hormone example (Roess et al . ,  2000) . The FRET analysis 
cou ld be taken further, to determine if FRET is dependent on  the signal ing 
potential of  the receptor ,  and potential ly proving that the d imer is the form of 
the receptor that is activated . If possible, the kinetics of d imer association and 
disassociation cou id be determined both with in  caveolae and in an RNAi 
caveol in - 1  deficient mode l .  This could help determine why the signal ing 
potential of MCHR1  is g reater without cholesterol than with cholestero l .  
Final ly ,  more work shou ld be done with an even more physiologically 
relevant mode l ,  l i ke the 3T3-L 1 adipose cel ls .  Additional  work should be done 
to visual ize MCHR 1  in adipocytes using f luorescent  microscopy, and 
conti nuing on i nto confocal m icroscopy. Very pre l im inary work performed (not 
reported due to t ime const raints) on  the confocal m icroscope showed that 
there was co-local izat ion visu al ized between caveol in - 1  and MCHR 1 . This 
work should be contin ued to better verify the co- local izat ion and determine 
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the effects of M C H  treatment in the physio logical ly re levant 3T3 model . I f  a 
better iso lat ion method cou ld be determined , then further work with l ip id 
iso lat ions cou ld be performed . I n  attempts to perform a sucrose gradient with 
3T3-L 1 d iffe rent iated adipocytes, there was beautifu l d istribution of caveol in - 1  
seen ,  but  there was too l ittle MCHR1  to  successful ly b lot for the receptor .  
Fina l ly ,  more stud ies should be done o n  the changes seen i n  the 
receptor weight  before and after MCH treatment.  This was performed on ly 
three t imes, and more data should be col lected to verify that there is a change 
in the upper weight densities on the western b lots . 
Significance 
Treatment of obesity has become a very important goal of d rug 
companies. I n it ia l  work with MCHR- 1  i nh ib itors has shown much promise i n  
an imal  mode ls ,  bu t  there is  potential for problems to  occur i n  human tria ls .  I n  
this way, i t  i s  very important t o  understand t he  complete satiety pathway 
identify poss ible compl icat ions. Understand ing the purpose of MCHR1 i n  
ad ipose cel l s  and  t he  signal ing properties o f  t he  receptor may help i n  
understand ing t he  overal l effects o f  inh ib itors on  the h uman body. As obesity 
is a growing epidemic ,  there is a greater need for a weight-loss booster. I n  the 
cases of i nd ividuals who eat health i ly and exercise regu larly and yet sti l l  
cannot lose weight ,  understanding the hormonal pathway cou ld spur  a new 
method of treatment to correct their imbalance and help them succeed. To be 
successfu l  i n  the treatment of obesity, the entire satiety pathway, inc luding 
MCH and its effect on peripheral t issues,  must be examined . 
Appendix 1 
Solution Recipes 
1Q_X Phosphate Buffered Sal ine 
To 800 mis of  d H20, add : 
80g N aCl  
2g KCI 
1 4 .4  g Na2HP04 
2.4 g KH2P04 
p H  to 7.4 and bring  u p  to 1 l 
PBS-_I 
To 1 Liter of 1 X PBS,  add 1 m l  of Tween-20 
5X Bradford Reagent 
1 )  Dissolve 1 OOmg Coomasie Blue in  50ml of EtOH 
2) Add 1 OOm l  85% Phosphoric acid 
3) Add 50ml d H20 
4) Fi lter  i nto c lean container 
25m M  Mes (Acros Organics) 
0 . 1 5  M NaCl 
pH to 6.5 
400 ml M BS add : 
1 3 .25g Na2C03 
pH to 1 1  and fi l l  to 500 ml 
Add to  400 m l  d H20 : 
26 .6  g Na2C03 
pH to 1 1  and fi l l  to 500 ml 
To 500 ml o f  M BS add  0.5 of Triton X- 1 00 
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25m M  Tris 
250mM Sucrose 
5X Lamel l i  Sample Buffer 
3. 75m l, 1 .OM Tris HCl,  pH 6 .8  
1 .5g s os 
0 .075g Bromophenol Blue 
1 . 1 6g Dith iothreitol (Cleland 's Reagent) 
Br ing up to 7.5 ml d H20. Add 7.5 m l  glycero l .  
1 OX SOS Runni ng Buffer 
30 .3g Tris Base 
1 44g Glycine 
1 0g s o s  
Bring u p  to 1 Liter in  dH20 
Towbins Transfer Buffer 
To 1 Liter of water ,  add : 
1 1 .6 g g lycine 
23 .2 g Tr is Base 
1 .48 g SDS 
800 m l  methanol 
Br ing vol ume to 4 Liters with water 
1 OX Tris-Buffered Sal ine (TBS) 
87.669 NaCl 
1 2 . 1 1 g  Tr is Base 
4ml HCl  
p H  to  8 .0  then bring up to  1 l with d H20 
To 1 ml of TBS add 500 of Tween -20 
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